Form 4: Recursion Pharmaceuticals Director Receives Stock Grant
Insider Transaction (Form 4)
Dean Y Li, a Director of Recursion Pharmaceuticals, Inc., received 3,378 shares of common stock on October 1, 2026.
Summary
- Grant/award: acquired 3,378 Class A Common Stock on October 1, 2026; holds 1,476,707 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Dean Y Li — Director
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-10-01 | Grant/award | Class A Common Stock | 3,378 | — | — | 1,476,707 |
Key Dates
| Date | Description |
|---|---|
| 2026-10-01 | Grant/award (3,378 shares) |
Keywords
insider transaction, Form 4, RXRX, RECURSION PHARMACEUTICALS, INC., neutral, Dean Y Li
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.